NY-METLIFE
15.10.2020 11:02:06 CEST | Business Wire | Press release
MetLife, Inc. (NYSE: MET) today announced a number of changes to its senior leadership team. All changes are effective on January 1, 2021, unless otherwise noted.
Executive Vice President and President of the Latin America region Oscar Schmidt will retire after a distinguished 26-year career with the company. He will step away from his executive position on December 31, 2020, and will stay on through the end of March 2021 to assist with the leadership transition.
“Over the past two and a half decades, Oscar has helped us grow and develop our Latin America business, building a well-diversified portfolio of businesses across the region,” said MetLife President and CEO Michel Khalaf. “Under his strong leadership, we have grown to become the largest life insurer in Latin America – a distinction achieved organically and through a number of acquisitions.”
Succeeding Schmidt as Regional President, Latin America, will be Eric Clurfain , Executive Vice President and Chairman, President and CEO of MetLife Japan K.K., subject to the necessary approvals. He will report to Khalaf.
“With more than two decades of insurance experience, Eric has a proven track record of building high-performing teams and businesses and a deep commitment to our associates and customers,” Khalaf said. “Over the past two years, his intense focus on business execution and customer centricity has driven culture change in Japan and delivered strong results in support of our Next Horizon strategy. Under his leadership, I am confident LatAm will continue to be a growth engine for MetLife.”
Clurfain’s career path has spanned numerous geographies and strategic leadership responsibilities. Prior to his current role, Clurfain was Regional Head for EMEA with oversight over the region’s 25 markets. Previously, he was Regional Head for Central and Eastern Europe after serving as General Manager of MetLife in Turkey. Earlier in his career with AIG/Alico, Clurfain lived and worked in Latin America.
Succeeding Clurfain as Executive Vice President and Chairman, President and CEO of MetLife Japan K.K. will be Dirk Ostijn , Head of EMEA, subject to the necessary approvals. Ostijn will report to Executive Vice President Kishore Ponnavolu , Regional President, Asia.
“Dirk has successfully led our EMEA region through a challenging operating environment,” Khalaf said. “Under his leadership, the EMEA team built strong momentum with a robust pipeline of new business opportunities, a relentless focus on efficiency, and a diversified model spanning more than 25 markets. I know his exemplary leadership, deep insurance expertise, and passion for the customer will be welcomed and appreciated by our team in Japan.”
With more than 30 years of experience, Ostijn’s career encompasses all aspects of the life insurance industry, including product, finance, operations, customer service and technology. He also spent more than a decade managing insurance brokerage operations, served as a General Manager in Belgium and held regional roles such as chief financial officer and head of strategic initiatives.
Succeeding Ostijn as Head of EMEA will be Nuria Garcia , Senior Vice President and Deputy Head of EMEA. She will report to Khalaf.
“Nuria has a strong focus on business development and partnerships as well as a passion for the customer,” Khalaf said. “She is a highly effective leader who can connect internal and external stakeholders to collaborate across business, function and market. Her leadership played an integral role in the region’s continued strong performance, and I have every confidence that she will continue to build on this track record going forward.”
Garcia has more than 20 years of experience in EMEA spanning distribution, marketing, operations and finance, both with MetLife and GE.
“Taken together, these moves demonstrate not only our commitment to talent development and succession planning, but our deep bench of leaders who are ready to step up immediately and deliver value to our customers and shareholders,” Khalaf said.
About MetLife
MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help its individual and institutional customers navigate their changing world. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com .
Forward-Looking Statements
The forward-looking statements in this disclosure, using words such as “will,” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it has no obligation to correct or update any of these statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201015005425/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom